CIK 1832749
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 100.00% | 5 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | PRAX | Praxis Precision Medicines, Inc. | Health Care | 42.83% |
| 2 | ANRO | Alto Neuroscience, Inc. | Health Care | 30.26% |
| 3 | LENZ | LENZ Therapeutics, Inc. | Health Care | 18.77% |
| 4 | KRRO | Korro Bio, Inc. | Health Care | 6.32% |
| 5 | CRBU | Caribou Biosciences, Inc. | Health Care | 1.82% |
5/5 names classified · sector 100.0% of weight · industry 100.0% · mkt cap 100.0%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 100.0% of the book is sector-classified (unclassified names shown, never dropped).
Only 0% of book weight classified — the grid is NOT representative of the whole book.
Classified: 0.0% of book weight (0/5 names) · unclassified 100.0%: PRAX, ANRO, LENZ, KRRO, CRBU. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| PRAXPRAXIS PRECISION MEDICINES I | 66K | 66K | 66K | 66K | 66K | 66K | $21M |
| ANROALTO NEUROSCIENCE INC | 668K | 668K | 668K | 668K | 668K | 668K | $15M |
| LENZLENZ THERAPEUTICS INC | 1.0M | 1.0M | 1.0M | 1.0M | 1.0M | 1.0M | $9M |
| KRROKORRO BIO INC | 277K | 277K | 277K | 277K | 277K | 277K | $3M |
| CRBUCARIBOU BIOSCIENCES INC | 474K | 474K | 474K | 474K | 474K | 474K | $900,727 |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
